IP Library Granted Patent US 9,845,509
Granted Patent B2
US 9,845,509 · App. 14/075,944 · Granted Dec 19, 2017

Compositions and methods to detect Legionella pneumophila nucleic acid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,845,509
App. No.
14/075,944
Granted
Dec 19, 2017
Kind
B2
Abstract

Compositions are disclosed as nucleic acid sequences that may be used as amplification oligomers, including primers, and detection probes that hybridize specifically to Legionella pneumophila 23S rRNA sequences or DNA encoding 23S rRNA. Reaction mixtures are disclosed that contain oligonucleotides for the in vitro amplification and/or detection of Legionella pneumophila 23S rRNA sequences or DNA encoding 23S rRNA. Methods are disclosed for amplifying and/or detecting the presence of L. pnuemophila in samples by using the disclosed compositions in in vitro methods that include nucleic acid amplification and/or detection of a 23S rRNA sequence or DNA encoding the 23S rRNA sequence to produce a detectable amplification product. Reaction mixtures are disclosed that contain oligonucleotides for the in vitro amplification and/or detection of Legionella pneumophila 23S rRNA sequences or DNA encoding 23S rRNA.

Claims (38)

1. A method for the amplification of Legionella pneumophila 23S nucleic acid present in a sample, the method comprising the steps of:

(A) contacting the sample with a capture probe that hybridizes to a Legionella pneumophila 23S target nucleic acid and separating the target nucleic acid away from other components of the sample;

(B) contacting the separated target nucleic acid from step (A) with a set of oligonucleotides, the set of oligonucleotides comprising:

(i) a first amplification oligonucleotide, the base sequence of which consists of SEQ ID NO:87;

(ii) a second amplification oligonucleotide, the base sequence of which consists of SEQ ID NO:71 joined at its 5′ end to a promoter sequence; and

(iii) a blocker oligonucleotide, the base sequence of which is at least 80% identical to SEQ ID NO:84; and

(C) performing a transcription associated amplification reaction to generate amplification product from the target nucleic acid using the set of oligonucleotides.

2. The method of claim 1 , wherein the base sequence of the 5′ promoter base sequence consists of the base sequence of SEQ ID NO:90.

3. The method of claim 2 , wherein the base sequence of the second amplification oligonucleotide consists of SEQ ID NO:75.

4. A reaction mixture for performing the isothermal amplification of a Legionella pneumophila 23S nucleic acid, wherein the reaction mixture comprises:

(A) a Legionella pneumophila 23S target nucleic acid that has been separated from components of a biological sample derived from a human;

(B) a first amplification oligonucleotide, the base sequence of which consists of SEQ ID NO:87;

(C) a second amplification oligonucleotide, the base sequence of which consists of SEQ ID NO:71 joined at its 5′ end to SEQ ID NO:90; and

(D) a blocker oligonucleotide, the base sequence of which is at least 80% identical to SEQ ID NO:84.

5. The reaction mixture of claim 4 , wherein that base sequence of the second amplification oligonucleotide consists of SEQ ID NO:75.

6. A method for the detection of Legionella pneumophila 23S nucleic acid present in a sample, the method comprising the steps of:

(A) providing a sample suspected of containing Legionella pneumophila 23S target nucleic acid;

(B) contacting the sample from step (A) with a set of oligonucleotides, the set of oligonucleotides comprising

(i) a first amplification oligonucleotide, the base sequence of which consists of SEQ ID NO:87,

(ii) a second amplification oligonucleotide, the base sequence of which consists of SEQ ID NO:71 joined at its 5′ end to a promoter sequence, and

(iii)a blocker oligonucleotide, the base sequence of which is at least 80% identical to SEQ ID NO:84;

(C) performing a transcription associated amplification reaction to generate amplification product from the target nucleic acid using the set of oligonucleotides; and

(D) detecting the amplification product in real time by specifically hybridizing the amplification product with a hairpin detection probe under conditions that allow hybridization, the base sequence of which consists of

(i) a target specific sequence that specifically hybridizes to an amplification product target sequence selected from the group consisting of SEQ ID NO:97, SEQ ID NO:98, and the complement of SEQ ID NO:97 or 98, and

(ii) a closing sequence,

wherein detection of the amplification product indicates the presence of Legionella pneumophila in the sample.

7. The method of claim 6 , wherein the 5′ promoter sequence consists of the base sequence of SEQ ID NO:90.

8. The method of claim 6 , wherein the target specific sequence and the closing sequence are a sequence selected from the group consisting of SEQ ID NO:88, SEQ ID NO:89, and the complement of SEQ ID NO:88 or 89.

9. The method of claim 8 , wherein the hairpin detection probe further comprises at least one label selected from the group consisting of: a fluorescent label, a quencher label, a chemiluminescent label, a fluorescein label, a DABCYL label and combinations thereof.

10. The method of claim 8 , wherein the hairpin detection probe further comprises a label pair selected from the group consisting of: a F/Q pair, a F/DABCYL pair, a fluorescein/Q pair, a luminescent/adduct pair, a Forrester energy transfer pair, and a fluorescein/DABCYL pair.

11. The method of claim 10 , wherein one member of the pair is attached to the 5′ end of the hairpin detection probe and another member is attached to the 3′ end of the hairpin detection probe.

12. The method of claim 6 wherein the hairpin detection probe further comprises a label pair selected from the group consisting of: a F/Q pair, a F/DABCYL pair, a fluorescein/Q pair, a luminescent/adduct pair, a Forrester energy transfer pair, and a fluorescein/DABCYL pair.

13. The method of claim 12 , wherein one member of the pair is attached to the 5′ end of the hairpin detection probe and another member is attached to the 3′ end of the hairpin detection probe.

14. The method of claim 6 , wherein the hairpin detection probe base sequence contains one or more substituted sugar moiety selected from the group consisting of 2′ methoxy substitutions and 2′ halide substitutions.

15. The method of claim 14 , wherein the hairpin detection probe further comprises at least one label selected from the group consisting of: a fluorescent label, a quencher label, a chemiluminescent label, a fluorescein label, a DABCYL label and combinations thereof.

16. The method of claim 14 , wherein the hairpin detection probe further comprises a label pair selected from the group consisting of: a F/Q pair, a F/DABCYL pair, a fluorescein/Q pair, a luminescent/adduct pair, a Forrester energy transfer pair, and a fluorescein/DABCYL pair.

17. The method of claim 16 , wherein one member of the pair is attached to the 5′ end of the hairpin detection probe and the other member is attached to the 3′ end of the hairpin detection probe.

18. The method of claim 6 , wherein the base sequence of the second amplification oligonucleotide consists of the base sequence of SEQ ID NO:75; and the base sequence of the hairpin detection probe consists of the base sequence of SEQ ID NO:88 or the base sequence of SEQ ID NO:89.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2017
From: BUNGO, JENNIFER J.; HOGAN, JAMES J.; POLLNER, REINHOLD B.; HUDSPETH, MARIE K.; KAPLAN, SHANNON K.; MARLOWE, ELIZABETH M.
To: GEN-PROBE INCORPORATED
Reel/Frame 043344/0599 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 032059 0467 Recorded Jul 17, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; SUROS SURGICAL SYSTEMS, INC.; BIOLUCENT, LLC; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 036126/0813 →
SECURITY AGREEMENT Recorded Jan 16, 2014
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED; DIRECT RADIOGRAPHY CORP.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 032059/0467 →